Jeena Sikho Lifecare Ltd

• Approval received for clinical trials on 4 new health products • Trials include anti-diabetes, constipation relief, bowel movement improvement, and blood pressure control • Study involved 60-100 subjects, showing positive safety and efficacy results • Clinical trial reports available on the company website

🔍 Overview of the Clinical Trial Approval

Jeena Sikho Lifecare has announced approval to conduct clinical trials for four products: SDM02 tablets (anti-diabetes), Shuddhi XS Syrup (constipation), Petshuddhi Churna (bowel movement improvement), and Shuddhi Dr. B P Care tablets (hypertension).

🩺 Study Details and Outcomes

1. SDM02 Tablets: Pre-clinical study on diabetic rats showed efficacy with no mortality or adverse effects at a dose of 2g/kg over 21 days.
2. Shuddhi XS Syrup: Clinical trial on 60 subjects with constipation reported 92% relief without adverse events.
3. Petshuddhi Churna: Retrospective study on 100 patients showed significant improvement in bowel movement and stool consistency, with no adverse events.
4. Shuddhi Dr. B P Care Tablets: Clinical trial on 60 hypertensive patients showed significant reduction in blood pressure and heart rate within 2-3 hours, effects sustained for 6 hours, no adverse effects noted.

📊 Quantitative Data

• SDM02: Dose of 2g/kg in rats; no mortality over 21 days.
• Shuddhi XS Syrup: 60 subjects, 92% reported relief.
• Petshuddhi Churna: 100 patient records analyzed.
• Shuddhi Dr. B P Care: 60 patients with sustained blood pressure reduction.

📖 Documentation and Transparency

The company has provided detailed clinical trial reports, prepared under Good Laboratory Practices by recognized institutions, accessible on their website.

🤔 Perception for Investors

These approvals emphasize the company's commitment to scientific validation of products, which may enhance product credibility and future market acceptance. The detail of positive safety and efficacy outcomes could reflect an emphasis on regulatory compliance and quality assurance.

Overall, this update provides useful information regarding the development pipeline and scientific assessment standards that the company is following.